Johnson & Johnson to acquire Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has announced its largest biotech acquisition in over a year, agreeing to purchase Intra-Cellular Therapies for $14.6 billion. The deal highlights the ... Read More
Breakthrough in mental health treatment: Intra-Cellular’s Caplyta emerges as a beacon of hope for schizophrenia patients
In a significant development for schizophrenia management, Intra-Cellular Therapies has announced impressive outcomes from a late-stage, Phase III clinical trial evaluating Caplyta (lumateperone) for its ... Read More